HTT-I is an inborn error of tyrosine metabolism caused by a deficiency of fumarylacetoacetase. an enzyme most abundantly present in the liver and kidney (I). HTT-I manifests with either acute hepatic failure during the neonatal period or with liver cirrhosis, rickets, and renal tubulopathy in infancy. The treatment with a low-tyrosine, low-phenylalanine diet usually ameliorates the clinical symptoms and improves liver function. Biochemical monitoring of the patients is performed by regular analyses of plasma amino acids and AFP concentration (2, 3) . However, even during the most strict diet, the accumulation of toxic tyrosine metabolites persists, leading to an inevitable progression of the liver disease with a high risk of malignancy. HCC develops in at least 37% of patients surviving beyond the age of 2 y (4). Because of the high risk of cancer and the poor prognosis, an early liver transplantation is today the treatment of choice for these children. However, the recent finding of restraining the accumulation of toxic metabolites by 4-hydroxyphenylpyruvate dioxygenase inhibition may offer an alternative therapy (5) .
AFP, an oncodevelopmental glycoprotein, is produced primarily by the fetal yolk sac and liver (6) . In addition, increased AFT production is associated with hepatic regeneration and malignancy (7) . In tyrosinemia, the liver always produces elevated levels of serum AFP (8) . No exact analyses concerning the effect of the dietary balance and the liver function on the serum AFP concentration in HTT-I are available. Malignant transformation in patients with tyrosinemia induces a further rise in the AFP concentration, but early recognition of the developing malignancy may be delayed because of constantly high and fluctuating AFP levels.
We have studied the expression of two tumor markers, CA 125 and CA 19-9, in patients with HTT-I. Both markers are detected by MAb originally raised against cystadenocarcinoma and colorectal cell line, respectively (9, 10). They are known to be expressed in adult patients with various gastrointestinal malignancies ( l l , 12), and elevated serum levels have been reported in patients with HCC (13, 14) . On the basis of these data and realizing the possible pitfalls of serum AFP measurements, we started to use measurements of serum CA 125 and CA 19-9 to detect tumors in the HTT-I livers at an early stage of the disease and to gain information on the biology of CA 125 and CA 19-9 in this disease. Moreover, the relationship of serum AFP concentrations to the new tumor markers and to the clinical and metabolic state in children with tyrosinemia was studied in detail.
PATIENTS AND METHODS
Palienls. Ten patients, three girls and seven boys with HTT-I, were followed up for 0.2 to 2.6 y after diagnosis at the Children's Hospital, University of Helsinki, and the University Hospital of elevated rapidly above the reference range during the first 4 mo before early liver transplantation.
2. Chronic type c?fHTT-I. Patients 9 and 10 with chronic type of disease had normal values at diagnosis, which slowly increased during the follow-up (Fig. 1 B) . The highest serum CA 125 peaks in patient 10 coincided with the episodes of porphyria crises and neurologic symptoms (Fig. 2) . Patients 7 and 8, with late manifestation of the disease, constantly showed normal serum CA 125 values. 3. Hepatic malignancj~. Patient 7 died of HCC without any alteration in her serum CA 125 level. whereas her serum AFP concentration increased with advancing disease. Also, serum CA 125 did not elevate in the one patient (patient 3) with areas of malignant cell clusters in her liver at transplantation before this operation.
No significant correlation between serum CA 125 values and laboratory parameters for the metabolic control of HTT-I, liver function, or other tests was noted.
Serum CA Concentration. Serum CA 19-9 values varied from <5.6 to 85 IU/L and were within the normal range in 182 (97%) of the 188 samples. The type of tyrosinemia or the occurrence of malignancy did not affect the serum CA 19-9 levels. Slightly elevated concentrations (85 IU/L) were seen in only one patient at diagnosis (patient I). He was the youngest patient and had the most severe and acute type of HTT-I, manifesting at the age of 6 wk with acute liver failure. His CA 19-9 level normalized after institution of dietary treatment supplemented with intravenous glutathione.
Serum AFP Cuncmtration. Serum AFP was measured in a total of 337 samples. In all patients. serum AFP levels were elevated at diagnosis and ranged from 1 500 to 213 000 pg/L, corresponding to 6.0 to 17 725 multiples of the age-related (Table 1) . The AFP levels decreased in all patients after the institution of therapy and with advancing age but still remained abnormally high.
AGE (years)
1. Acule tjpe of HTT-I. All patients with acute tyrosinemia had a fluctuating serum AFP level without any clear correlation with metabolic control or clinical picture. The lowest and highest AFP values in these six patients ranged from 14 000 to 28 000 pg/L (mean, 2 1 000 pg/L) and from 48 000 to 132 000 pg/L (mean, 82 000 pg/L), respectively. corresponding to a 1.9-to 7.6-fold variation in the serum AFP level.
2. Chronic type of HTT-I. The patients with chronic disease had rather stabile serum AFP levels during the long follow-up period. Two clear exceptions with more than 10-fold increases in serum AFP levels were noted: in patient 10 before porphyria crises (from 1 000 to 2 1 000 pg/L. Fig. 2 ) and in patient 7 before diagnosis of HCC (from 25 000 to 250 000 pg/L).
3. Hepatic malignancj3. One of the patients with the acute type of HTT-I (patient 3) had areas of malignant cell clusters in her liver at transplantation, but she had only 2-fold increases in the serum AFP level (from 27 000 to 55 000 pg/L) during the preceding 2 mo. The other patient with the chronic type of HTT-I (patient 7) had a 10-fold increase in the serum AFP level (from 25 000 to 250 000 pg/L) before she died of HCC.
A positive correlation between serum AFP level and some markers for the metabolic control (serum methionine, n = 15 1. p = 0.0002; tyrosine. n = 157, p = 0.0002) and parameters for liver function (serum alkaline phosphatase. n = 95. p = 0.0001: total bilirubin, n = 61, p = 0.0001: conjugated bilirubin, n = 33. p = 0.002: and 7-glutamyl transpeptidase, n = 77. p = 0.0001) was observed. DISCUSSION HTT-I is seen at diagnosis with either acute, rapidly evolving hepatic failure or a more chronic hepatopathy with sequential progression from micronodular to macronodular cirrhosis and regenerative foci susceptible to malignant transformation (17) . The liver damage is thought to be caused by toxic tyrosine metabolites, maleylacetoacetate and succinylacetoacetate. which accumulate regardless of an adequate dietary therapy (3).
The tumor markers CA 125 and CA 19-9 are elevated in adults with gastrointestinal malignancy and are thus candidate markers for malignant transformation in the pathologic liver tissue in hereditary tyrosinemia. The possible oncofetal nature of CA 125 and CA 19-9 is suggested by their strong expression in fetal tissues (9, l I, 12) . Our results on CA 125 support this view: the enhanced production of CA 125 in HTT-I, analogous to AFP. may be a consequence of a fetal type of gene expression in tyrosinemia. In contrast to CA 125 and AFP, the pattern of CA 19-9 expression was not shifted to such a fetal direction.
Most ofthe patients with acute HTT-I had remarkably elevated serum CA 125 levels during the first months of the disease, which gradually normalized after the institution of dietary therapy. These children also had radiologically detectable liver nodules at diagnosis. High initial serum CA 125 concentration may thus indicate a fulminant onset of the disease and reflect the metabolic state within the liver. This view is supported by the association of elevated serum CA 125 level and episodes of porphyria. However, no significant correlation between serum CA 125 level and laboratory parameters for metabolic state was noted. The patients with a chronic type of disease and long follow-up periods showed slowly increasing serum CA 125 levels. The increasing serum CA 125 level in these patients can reflect the progression of liver damage and development of macronodular cirrhosis.
In contrast to serum CA 125, the concentrations of CA 19-9 were practically always within reference values. This was also the case in the two patients with HCC. Serum CA 19-9 measurements are thus not valuable in the follow-up of patients with HTT-I.
Serum AFP measurements have been used in the early diagnosis of hereditary tyrosinemia (8, 18) and as an indicator of hepatic malignancy. The constantly elevated levels of AFP, however, hamper its use as a marker for the development of malignancy in hereditary tyrosinemia. The AFP levels at diagnosis varied over a wide range from patient to patient, possibly indicating various degrees of liver damage in these children. During the follow-up, the concentrations remained abnormally high, and minor fluctuations occurred in all patients. The noted clear correlations between serum AFP level and laboratory parameters of the liver function suggest that the fluctuations in serum AFP levels may reflect the pathologic condition of the liver in HTT-I. In two children, a marked elevation in serum AFP levels during the therapy was noted: in one of them, hepatic malignancy was subsequently detected. and in the other one the increase in serum AFP level preceded episodes of porphyria. Thus, even a clear increase in the serum AFP level does not always mean the development of malignancy in the liver. Furthermore, one of the two patients with malignancy (histologically proven at transplantation, but clinically not evident) did not have a clear elevation in the serum AFP level.
We conclude that fluctuations in serum AFP concentration limit its usefulness in early detection of developing hepatic malignancies or porphyria crises in children with tyrosinemia. Serum CA 125 levels were mostly highly elevated at the early phase of acute tyrosinemia. Measurements of serum CA 125 or CA 19-9 levels do not, however, seem to offer diagnostic tools for determining whether HCC is developing in these patients because the levels were normal in the two patients in whom a histologically proven overt hepatic malignancy developed.
